Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension-Reference-Cited by-同舟云学术

Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension

Published:2005 Issue: Volume: Page:251-284
ISSN:0070-2153
Container-title:Current Topics in Developmental Biology
language:
Short-container-title:

Author:

Schermuly Ralph Theo,Ghofrani Hossein Ardeschir,Weissmann Norbert

Publisher

Elsevier

Reference170 articles.

1. Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension;Abe;J. Cardiovasc. Pharmacol.,2001

2. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues;Ahn;Adv. Exp. Med. Biol.,1991

3. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension;Aranda;Anesth. Analg.,1999

4. ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog;Archer;J. Am. Coll. Cardiol.,1986

5. Prostanoid therapy for pulmonary arterial hypertension;Badesch;J. Am. Coll. Cardiol.,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association of urinary prostaglandins with uric acid in hyperuricemia patients;BMC Nephrology;2022-09-03

2. Untapped Potential: Therapeutically Targeting Eicosanoids and Endocannabinoids in the Lung;Clinical Pharmacology & Therapeutics;2021-02-13

3. “Treat and repair” strategy for shunt lesions: a critical review;Pulmonary Circulation;2020-04

4. Assessment of Operability of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease;Circulation Journal;2014

5. Hypoxia-inducible factor pathway and diseases of the vascular wall;Journal of Vascular Surgery;2013-07